WO2021054440A1 - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- WO2021054440A1 WO2021054440A1 PCT/JP2020/035438 JP2020035438W WO2021054440A1 WO 2021054440 A1 WO2021054440 A1 WO 2021054440A1 JP 2020035438 W JP2020035438 W JP 2020035438W WO 2021054440 A1 WO2021054440 A1 WO 2021054440A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulfate
- nasal
- chondroitin
- polysaccharide
- sulfated
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 208000000592 Nasal Polyps Diseases 0.000 claims abstract description 92
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 82
- 239000005017 polysaccharide Substances 0.000 claims abstract description 82
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Polymers FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 65
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 44
- 229940043138 pentosan polysulfate Drugs 0.000 claims abstract description 44
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 41
- 208000016366 nasal cavity polyp Diseases 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims abstract description 23
- 229920002567 Chondroitin Polymers 0.000 claims abstract description 22
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims abstract description 22
- 229920000288 Keratan sulfate Polymers 0.000 claims abstract description 21
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims abstract description 21
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 20
- 229960000633 dextran sulfate Drugs 0.000 claims abstract description 20
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims abstract description 19
- 229920002581 Glucomannan Polymers 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 229940046240 glucomannan Drugs 0.000 claims abstract description 19
- 229920000045 Dermatan sulfate Polymers 0.000 claims abstract description 17
- 229920001202 Inulin Polymers 0.000 claims abstract description 16
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 16
- 229940029339 inulin Drugs 0.000 claims abstract description 16
- 229940051593 dermatan sulfate Drugs 0.000 claims abstract description 15
- 150000004676 glycans Chemical class 0.000 claims abstract 4
- -1 polysaccharide chondroitin sulfate Chemical class 0.000 claims description 49
- 201000009890 sinusitis Diseases 0.000 claims description 32
- 210000003979 eosinophil Anatomy 0.000 claims description 25
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 19
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000003638 chemical reducing agent Substances 0.000 claims description 12
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 abstract description 29
- 239000004480 active ingredient Substances 0.000 abstract description 7
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 abstract description 4
- 150000004804 polysaccharides Chemical class 0.000 description 75
- 229920002683 Glycosaminoglycan Polymers 0.000 description 34
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 31
- 229920001499 Heparinoid Polymers 0.000 description 25
- 239000002554 heparinoid Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 239000007923 nasal drop Substances 0.000 description 22
- 229940100662 nasal drops Drugs 0.000 description 21
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 238000011534 incubation Methods 0.000 description 18
- 150000002772 monosaccharides Chemical class 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 14
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 14
- 230000001603 reducing effect Effects 0.000 description 13
- 229940061706 sulfated mucopolysaccharides Drugs 0.000 description 13
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 11
- 239000000654 additive Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 150000002016 disaccharides Chemical class 0.000 description 8
- 229940025770 heparinoids Drugs 0.000 description 8
- 210000003928 nasal cavity Anatomy 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 7
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 7
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 7
- 206010028735 Nasal congestion Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Polymers CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Polymers CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 238000005670 sulfation reaction Methods 0.000 description 6
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 159000000007 calcium salts Chemical class 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 159000000003 magnesium salts Chemical class 0.000 description 5
- 210000002850 nasal mucosa Anatomy 0.000 description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 229960000278 theophylline Drugs 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000019635 sulfation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 150000004823 xylans Chemical class 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 229920001221 xylan Polymers 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940107200 chondroitin sulfates Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229960002819 diprophylline Drugs 0.000 description 2
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 210000004086 maxillary sinus Anatomy 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 150000004028 organic sulfates Chemical group 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QGGOCWIJGWDKHC-FSIIMWSLSA-N (2s,3s,4r,5r)-2,4,5-trihydroxy-3-methoxy-6-oxohexanoic acid Chemical group OC(=O)[C@@H](O)[C@@H](OC)[C@H](O)[C@@H](O)C=O QGGOCWIJGWDKHC-FSIIMWSLSA-N 0.000 description 1
- IHADVZPGQYQGLH-PIYBLCFFSA-N (4r,5s,6r)-4,5,6,7-tetrahydroxyheptane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)CO IHADVZPGQYQGLH-PIYBLCFFSA-N 0.000 description 1
- HXBYBCASAVUYKF-GVYWOMJSSA-N (4r,5s,6r,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO HXBYBCASAVUYKF-GVYWOMJSSA-N 0.000 description 1
- HXBYBCASAVUYKF-YTQLPXDHSA-N (4r,5s,6s,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO HXBYBCASAVUYKF-YTQLPXDHSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- RGVPOXRFEPSFGH-UHFFFAOYSA-N 1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol Chemical compound COC1=C(OC)C(OC)=CC(CC2C3=CC(O)=C(O)C=C3CCN2)=C1 RGVPOXRFEPSFGH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000018963 Chondroitin Lyases Human genes 0.000 description 1
- 108010026719 Chondroitin Lyases Proteins 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018713 Gravitational oedema Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- IUTJITCLNLMFAJ-UHFFFAOYSA-N Linderone Natural products COC1=C(OC)C(=O)C(=C(O)C=Cc2ccccc2)C1=O IUTJITCLNLMFAJ-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000012898 Olfaction disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KYHQZNGJUGFTGR-UHFFFAOYSA-N Proxyphylline Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)C KYHQZNGJUGFTGR-UHFFFAOYSA-N 0.000 description 1
- NFQIAEMCQGTTIR-UHFFFAOYSA-N Repirinast Chemical compound C12=CC=C(C)C(C)=C2NC(=O)C2=C1OC(C(=O)OCCC(C)C)=CC2=O NFQIAEMCQGTTIR-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XQTARQNQIVVBRX-UHFFFAOYSA-N Tazanolast Chemical compound CCCCOC(=O)C(=O)NC1=CC=CC(C2=NNN=N2)=C1 XQTARQNQIVVBRX-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000238450 Todarodes pacificus Species 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000000328 arabinofuranosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229940073464 benzododecinium bromide Drugs 0.000 description 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MARKAJRMJIFCLH-UHFFFAOYSA-N benzoic acid 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=C(O)C=C1 MARKAJRMJIFCLH-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940096386 coconut alcohol Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229940026692 decadron Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000003009 desulfurizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- GSPKZYJPUDYKPI-UHFFFAOYSA-N diethoxy sulfate Chemical compound CCOOS(=O)(=O)OOCC GSPKZYJPUDYKPI-UHFFFAOYSA-N 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- GTDCHGNGVGRHQY-UHFFFAOYSA-N hexoprenaline sulfate Chemical compound [O-]S([O-])(=O)=O.C=1C=C(O)C(O)=CC=1C(O)C[NH2+]CCCCCC[NH2+]CC(O)C1=CC=C(O)C(O)=C1 GTDCHGNGVGRHQY-UHFFFAOYSA-N 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940125389 long-acting beta agonist Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940064748 medrol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- UNSKAUSCLTVFGO-FSIIMWSLSA-N methyl (2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical group COC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O UNSKAUSCLTVFGO-FSIIMWSLSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 1
- 229960004186 naphazoline nitrate Drugs 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229940052404 nasal powder Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- IEDOGKKOPNRRKW-UHFFFAOYSA-N octadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC IEDOGKKOPNRRKW-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 description 1
- 229950003837 ozagrel Drugs 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- FKNXQNWAXFXVNW-WBMJQRKESA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@H](O)[C@H](NC(C)C)CC FKNXQNWAXFXVNW-WBMJQRKESA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- PRLPAGCIZDCPKE-UHFFFAOYSA-N pyridine;sulfur monoxide Chemical compound S=O.C1=CC=NC=C1 PRLPAGCIZDCPKE-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 229950009147 repirinast Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960003090 seratrodast Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 229940094908 stearyl myristate Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950011558 tazanolast Drugs 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003742 xyloses Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
Definitions
- the present invention relates to a pharmaceutical composition containing a predetermined polysaccharide used as a shrinking agent for nasal polyps, a method for treating nasal polyps using a predetermined polysaccharide, and the like.
- Nasal polyps also called nasal polyps
- nasal polyps are fleshy growths of the nasal mucosa that form at the site of dependent edema in the lamina basement (usually around the opening of the maxillary sinus). It is a disease that often accompanies chronic sinusitis and exacerbates the nasal congestion symptoms of chronic sinusitis, and is one of the major diseases of nasal diseases (MSD Manual Professional Edition https://www.msdmanuals.com/). ja-jp).
- Various causes of nasal polyps such as edema due to increased vascular permeability, lamina limbal prolapse, and extracellular matrix accumulation are considered, and their association with various cytokines and growth factors has also been reported. ..
- As a growth factor the relationship between vascular endothelial growth factor and platelet-derived growth factor and nasal polyps has been reported (Non-Patent Document 1: Kawasaki Medical Association 35 (1): 39-50, 2009).
- Chronic sinusitis is said to have persistent respiratory symptoms such as nasal congestion, rhinorrhea, postnasal drip, and cough for more than 3 months, and its cause is viral, bacterial, fungal, allergic, or pathological condition.
- eosinophilia There is unknown eosinophilia, and other factors such as differences in nasal cavity morphology, living environment, and inheritance affect the formation of complex pathological conditions including nasal polyps (Non-Patent Document 2: Non-Patent Document 2:). Japan Otolaryngology Society Bulletin 2018, 121, 1118-1120).
- diseases associated with nasal polyps include eosinophil sinusitis and non-eosinophil sinusitis.
- eosinophil sinusitis is a designated intractable disease, and is an adult-onset intractable sinusitis showing severe nasal congestion and olfaction disorder due to bilateral multiple nasal polyps and viscous nasal discharge. Antibiotics are ineffective in treating the disease and respond only to oral steroids. Since the nasal cavity is filled with nasal polyps, nasal sinus surgery was performed to remove the nasal polyps, but there was a problem that the nasal polyps recurred immediately.
- Non-Patent Document 3 Japanese Patent Application Laid-Open No. 10-203988) and / or hyaluronic acid (Non-Patent Document 3: Indian Journal of Otolaryngology and Head & Neck Surgery 67 (3): 299-307, September 2015) and the like are used. Has been reported.
- Non-Patent Document 4 Ear-nasal immunoallergy 29 (3): 221-227, 2011
- Non-Patent Document 5 Allergology International 66 (2017) 594-602
- Patent 6436351 Japanese Patent Application Laid-Open No. 09-104636 Japanese Patent Application Laid-Open No. 10-203988
- the present invention provides a safe nasal polyp reducing agent or a method for treating nasal polyps, which exhibits an excellent shrinking effect on nasal polyps.
- a predetermined polysaccharide particularly a heparinoid or pentosan polysulfate (PPS), which is a kind of sulfated polysaccharide, significantly reduces nasal polyps, and completes the present invention.
- PPS pentosan polysulfate
- the present invention is as follows.
- Polysaccharide selected from polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosanpoly sulfate, chondroitin, glucomannan, inulin, and xylooligosaccharide as active ingredients.
- a nasal mushroom reducing agent selected from polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosanpoly sulfate, chondroitin, glucomannan, inulin, and xylooligosaccharide as active ingredients.
- the polysaccharide or a salt thereof is selected from polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosanpoly sulfate, chondroitin, glucomannan, and inulin, according to (1).
- Nasal mushroom reducing agent A nasal polyp reducing agent containing a sulfated polysaccharide or a salt thereof as an active ingredient.
- the sulfated polysaccharide is composed of a monosaccharide selected from D-galactosamine, D-glucuronic acid, L-iduronic acid, D-glucose, D-galactose, D-xylose, and L-arabinose.
- the nasal mushroom reducing agent according to (1b), wherein the monosaccharide may be partially acetylated.
- chondroitin sulfate Polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosanpolysulfate, chondroitin, glucomannan, inulin, and xylooligo, which are used to reduce nasal mushrooms in patients with chronic sinusitis.
- a pharmaceutical composition containing a polysaccharide selected from sugars or a salt thereof.
- the sulfated polysaccharide is composed of a monosaccharide selected from D-galactosamine, D-glucuronic acid, L-iduronic acid, D-glucose, D-galactose, D-xylose, and L-arabinose.
- the pharmaceutical composition according to (5b), wherein the monosaccharide may be partially acetylated.
- the pharmaceutical composition according to (5b) or (6), wherein the sulfated polysaccharide is polysulfated chondroitin sulfate, polysulfated dermatan sulfate, or pentosan polysulfate.
- the polysaccharide or a salt thereof is selected from polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosanpoly sulfate, chondroitin, glucomannan, and inulin, according to (11).
- Method. (13) A method for reducing nasal polyps, which comprises administering an effective amount of a sulfated polysaccharide or a salt thereof to a patient in need of treatment for nasal polyps.
- the sulfated polysaccharide is composed of a monosaccharide selected from D-galactosamine, D-glucuronic acid, L-iduronic acid, D-glucose, D-galactose, D-xylose, and L-arabinose.
- the method according to (13), wherein the monosaccharide may be partially acetylated.
- the sulfated polysaccharide is polysulfated chondroitin sulfate, polysulfated dermatan sulfate, or pentosan polysulfate.
- Predetermined polysaccharides especially sulfated polysaccharides such as heparinoids and pentosan polysulfate, are useful as effective and safe nasal polyp reducing agents at low doses.
- the polysaccharides used in the present invention include sulfated mucopolysaccharides and sulfated mucopolysaccharides selected from polysulfated mucopolysaccharides such as chondroitin sulfate, chondroitin, dermatan sulfate, keratane sulfate, heparan sulfate, and polysulfated chondroitin sulfate.
- sulfated polysaccharides including dextran sulfate and pentosanpolysulfate, and polysaccharides selected from glucomannan, inulin, and xylooligosaccharides.
- it is a polysaccharide selected from polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan, and inulin.
- the sulfated polysaccharide in the present invention is selected from D-glucosamine, D-galactosamine, D-glucuronic acid, L-isulonic acid, D-galacturonic acid, D-glucose, D-galactose, D-xylose, and L-arabinose.
- These monosaccharides may be partially acetylated, and are composed of a polysaccharide having one or more of the monosaccharides as a repeating unit and having a sulfate group.
- the sulfated polysaccharide used in the present invention has an average of 0.55 to 4 molecules, preferably an average of 0.6 to 2.9 molecules, and more preferably an average of 0.7 to 2 molecules per molecule of monosaccharide. Is.
- the sulfated polysaccharide used in the present invention has a sulfated group content of 10 to 70 w / w% according to the quantitative method specified in "Heparin-like substance" of the Japanese Pharmacy Non-Pharmaceutical Standard 2002. Some are preferred, more preferably sulfated polysaccharides having an organic sulfate group content of 10-65 w / w%.
- the main constituent monosaccharides are selected from D-galactosamine, D-glucuronic acid, L-iduronic acid, D-glucose, D-galactose, D-xylose and L-arabinose, some of which are monosaccharides.
- partially acetylated monosaccharides include naturally occurring monosaccharides such as acetylglucose, N-acetylglucosamine, acetylgalactose, N-acetylgalactosamine, and acetylxylose.
- the weight average molecular weight of the sulfated polysaccharide or salt thereof used in the present invention is about 1000 to 10,000,000, preferably about 4000 to 1,000,000.
- the weight average molecular weight used in the present specification is the following formula when there are Ni polymers having a molecular weight of Mi.
- Weight average molecular weight (Mw) ⁇ (Ni ⁇ Mi 2 ) / ⁇ (Ni ⁇ Mi) ) It is a value represented by.
- the weight average molecular weight means a value measured by gel permeation chromatography (GPC).
- the weight average molecular weight is, for example, the weight average molecular weight in terms of pullulan or polyethylene glycol measured by GPC using pullulan or polyethylene glycol as a reference substance.
- the weight average molecular weight can be measured by, for example, high performance liquid chromatography (Waters or Shimadzu Corporation), and Ohpak SB-804 and SB-803 (both Showa Denko KK) can be used as columns. ..
- As the mobile phase an aqueous solvent such as an aqueous solution of ammonium acetate or an aqueous solution of sodium chloride can be used, and the flow velocity can be 1.0 mL / min.
- a differential refractive index can be used in the detection method.
- the various sulfated polysaccharides used in the present invention can be obtained by the following methods.
- Sulfated polysaccharides are obtained by subjecting a sulfation reaction to a polysaccharide composed of a monosaccharide which may be partially acetylated and introducing a sulfate group.
- For the sulfation reaction prepare 10 to 30 mL of an ice-cooled solvent with respect to 1 g of the raw material polysaccharide, add a sulfate agent 2 to 6 times to 1 g of the raw material polysaccharide, and add 1 g of the raw material polysaccharide to this solution. Is added and reacted at 0 ° C. to 100 ° C.
- sulfated polysaccharide composed of a partially acetylated monosaccharide used in the present invention preferably 0% to 60% (molar ratio) of the constituent sugars of the sulfated polysaccharide is N-acetylated. Or it is O-acetylated.
- the sulfated polysaccharide may be used as a physiologically acceptable salt form, and the physiologically acceptable salt includes an alkali metal salt such as a sodium salt and a potassium salt, and an alkaline soil such as a calcium salt. Examples thereof include metal salts and magnesium salts, and a plurality of these salts are also included.
- sulfated polysaccharide in the present invention examples include sulfated mucopolysaccharide, dextran sulfate, pentosan polysulfate and the like.
- Preferred are polysulfated chondroitin sulfate, chondroitin sulfate, chondroitin, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate and pentosan polysulfate.
- polysulfated mucopolysaccharides such as chondroitin sulfate, chondroitin, dermatan sulfate, keratan sulfate and heparan sulfate, and polysulfated chondroitin sulfate are classified as sulfated mucopolysaccharides.
- Glucomannan, inulin, and xylooligosaccharides are classified as polysaccharides that do not fall under the above.
- the "mucopolysaccharide” is a long-chain amino sugar having a repeating unit of a disaccharide consisting of hexosamine and uronic acid or galactose as a basic structure.
- "Sulfated mucopolysaccharide” means a mucopolysaccharide having a sulfate group.
- the sulfated mucopolysaccharide of the present invention also includes naturally occurring mucopolysaccharides having a sulfate group in the sugar chain, mucopolysaccharides, and those obtained by further chemically modifying natural sulfated mucopolysaccharides.
- Polysulfated mucopolysaccharide is a sulfated mucopolysaccharide having more sulfate groups in the sugar chain, and in addition to naturally-derived polysulfated mucopolysaccharides, mucopolysaccharides and natural sulfated mucopolysaccharides are used. Further, chemically sulfated products are also included. Examples of sulfated mucopolysaccharides will be described below, but the overall structure depends on the type of proteoglycan formed by these sulfated mucopolysaccharides, the animal species in which these sulfated mucopolysaccharides are present, the tissue, the stage of development, and the like.
- Hexosamine broadly means a compound in which the hydroxyl group of hexose is replaced with an amino group, and specific examples thereof include D-glucosamine and D-galactosamine.
- uronic acid broadly means an aldose primary alcohol that has been oxidized to a carboxyl group, and specifically, D-glucuronic acid, L-iduronic acid, D-galacturonic acid and the like. Examples include naturally occurring uronic acid.
- Chodroitin sulfate is a substance separated from animal mucous secretions and cartilage tissue.
- chondroitin sulfate A and chondroitin sulfate C are chondroitin sulfate as sulfated mucopolysaccharides.
- D and E are sulfated mucopolysaccharides, which are also classified as polysulfated mucopolysaccharides.
- Chondroitin sulfate A (chondroitin tetrasulfate) has a repeating structure of N-acetyl-D-galactosamine (GalNAc) and D-glucuronic acid (GlcA) disaccharides having a sulfate group at the 4-position as a basic structure.
- Chondroitin sulfate C (chondroitin 6 sulfate) has a repeating structure of GalNAc and GlcA disaccharides having a sulfate group at the 6-position as a basic structure.
- low molecular weight chondroitin sulfate having a weight average molecular weight of 100,000 or less, preferably 10,000 to 50,000, can also be used.
- Low-molecular-weight chondroitin sulfate is obtained by decomposing natural chondroitin sulfate using an enzyme such as chondroitinase or chondroitin sulfate lyase.
- "Dermatan sulfate” is composed of a repeating disaccharide of iduronic acid (IdouA) and GalNAc, and has a basic structure having a sulfate group at the 4-position of GalNAc. Sometimes referred to as chondroitin sulfate B.
- Keatan sulfate consists of a repeating disaccharide in which galactose (Gal) and N-acetyl-D-glucosamine (GlcNAc) are alternately bound by ⁇ (1 ⁇ 4) and ⁇ (1 ⁇ 3) bonds, respectively, and is composed of GlcNAc.
- the 6-position always has a sulfated structure as a basic structure.
- Heparan sulfate is a polysaccharide N-acetyl, N-sulfate, or O-sulfate substituent containing D-glucosamine, D-glucuronic acid, and L-iduronic acid as constituent sugars.
- Chodroitin is a mucopolysaccharide having a basic structure of repeating disaccharides of GalNAc and GlcA and having a particularly small number of sulfate groups (usually 0.7 molecules or less per disaccharide unit). In addition to naturally derived substances such as bovine cornea, it can also be obtained by chemically desulfating chondroitin sulfate.
- the sulfated mucopolysaccharide used in the present invention is preferably a sulfated mucopolysaccharide having a repeating unit of a disaccharide consisting of N-acetyl-D-galactosamine or N-acetyl-D-glucosamine and uronic acid or galactose, and chondroitin sulfate.
- a disaccharide consisting of N-acetyl-D-galactosamine or N-acetyl-D-glucosamine and uronic acid or galactose
- chondroitin sulfate Dermatan sulfate, keratan sulfate, and heparan sulfate are more preferred.
- the sulfated mucopolysaccharide used in the present invention also includes a polysulfated mucopolysaccharide obtained by further sulfated chondroitin sulfate, dermatan sulfate, keratan sulfate and the like.
- the number of sulfate groups contained in the sulfated mucopolysaccharide of the present invention is not particularly limited, but usually an average of 0.55 to 4 molecules, preferably an average of 0.6 to 2.9 molecules, and more preferably an average of 0. It has a ratio of 7 to 2 molecules.
- the molecular weight of the sulfated mucopolysaccharide or a salt thereof used in the present invention varies depending on the type of polysaccharide and is not limited, but the average molecular weight thereof is about 10,000 to 1,000,000 by weight average, preferably 10000. It is preferably about 50,000.
- the origin of the sulfated mucopolysaccharide of the present invention is not particularly limited, but more preferable one is, for example, the above-mentioned naturally-derived mucopolysaccharide being sulfated by artificially performing a sulfate treatment. Can be mentioned.
- polysulfated mucopolysaccharide means a mucopolysaccharide in which more sulfate groups are substituted among the above-mentioned sulfated mucopolysaccharides, and specific examples thereof include polysulfated chondroitin sulfate and polysulfated dermatan sulfate. It is preferably polysulfated chondroitin sulfate.
- a method for further introducing a sulfate group into a sulfated mucopolysaccharide such as chondroitin sulfate A or C to obtain a polysulfated mucopolysaccharide a known method, for example, heating in a suitable solvent in the presence of a sulfate agent, is performed.
- a method of reacting can be mentioned.
- the sulfate agent is not particularly limited as long as it can achieve the purpose of polysulfation, but it is preferable to use a complex of anhydrous sulfuric acid and pyridine or triethylamine.
- the proportion of the sulfated agent used can be arbitrarily selected according to the desired sulfation rate (or sulfur content) of the sulfated mucopolysaccharide and the reaction conditions, but in general, 1 part by weight of the sulfated mucopolysaccharide to be multisulfated. It is used at a ratio of 2 to 10 parts by weight.
- the solvent include protic and aprotic solvents such as dimethylformamide.
- the reaction temperature and reaction time are not particularly limited as long as the desired sulfation rate can be achieved, but for example, the reaction is carried out at 40 to 90 ° C. for about 30 minutes to 20 days.
- the polysulfated mucopolysaccharide produced as described above can be purified by a purification operation commonly used for various modified polysaccharides. For example, an operation of neutralizing, desalting by dialysis, an operation of recovering a precipitate by adding an organic solvent, a recovery operation by freeze-drying, and the like can be mentioned.
- the polysulfated mucopolysaccharide may be used as a physiologically acceptable salt form, and the physiologically acceptable salts include alkali metal salts such as sodium salt and potassium salt, calcium salts and the like. Examples include alkaline earth metal salts and magnesium salts, and a plurality of these salts are also included.
- the "polysulfated chondroitin sulfate” is a polymer containing about 2 to 4 molecules, preferably about 2 to 3 molecules of sulfate groups per disaccharide unit composed of D-acetylgalactosamine and D-glucuronic acid.
- Examples of the polysulfated chondroitin sulfate include chondroitin sulfate D, chondroitin sulfate E, and heparinoids described in the Japanese Pharmacopoeia Non-Pharmaceutical Standards.
- it is a heparinoid substance described in the Japanese Pharmacopoeia Non-Pharmaceutical Standards.
- Polysulfated chondroitin sulfate includes naturally obtained ones such as chondroitin sulfate D and chondroitin sulfate E, as well as chondroitin components such as chondroitin and chondroitin sulfate (A, C, D, E), and chlorosulfate, concentrated sulfuric acid, and tri. It can be easily produced by a known method of reacting a sulfate agent such as a sulfur oxide-pyridine complex.
- Preferred polysulfated chondroitin sulfates include heparinoids described in the Japanese Pharmacopoeia Non-Pharmaceutical Ingredient Standards. Specifically, it is polysulfated chondroitin sulfate which shows the following values as physicochemical properties. a) Sulfate group content: 25.8-37.3% b) Extreme viscosity: 0.09 to 0.18
- Polysulfated chondroitin sulfate may be used in the form of a free acid derived from a sulfuric acid residue, but usually a base salt is used.
- Examples of the base salt include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt, and magnesium salt.
- Chondroitin sulfate D is isolated from shark cartilage and has a structure similar to chondroitin sulfate C, and its basic structure has sulfate groups at positions 2 and 3 of GlcA in addition to the 6-position of GalNAc.
- Chondroitin sulfate E (chondroitin 4,6 sulfate) is isolated from Japanese flying squid cartilage and has a structure similar to chondroitin sulfate C, and its basic structure has sulfate groups at positions 4 and 6 of GalNAc.
- Polysulfated dermatan sulfate is synthesized by chemically introducing a sulfate group into dermatan sulfate, which is a natural sulfated mucopolysaccharide having a repeating sugar unit consisting of N-acetylgalactosamine and L-iduronic acid. It means dermatan polysulfate that is naturally occurring and dermatan polysulfate, or one that is synthesized by chemically introducing a sulfate group into the sulfate.
- the number of sulfate groups introduced is not particularly limited, for example, more than 1 per repeating sugar unit, up to 4, preferably 1.3-4, more preferably 2-4. Can be mentioned.
- the weight average molecular weight of the polysulfated dermatan sulfate of the present invention is, for example, about 1,000 to tens of thousands. Sulfated polysaccharides other than the above used in the present invention will be described below.
- “Dextran sulfate” is a straight chain of glucose bound to ⁇ (1 ⁇ 6) and a variety of usual from 1000 to thousands of daltons (Da) to hundreds of thousands of Da starting from the branch of ⁇ (1 ⁇ 3) bond.
- Pentosan polysulfate is a semi-synthetic sulfated polysaccharide containing a mixture of polyvalent anionic polysaccharides with D-xylose and / or L-arabinose as the constituent monosaccharides. Pentosan polysulfate is produced by the chemical sulfation of polysaccharides (eg, xylan) obtained from wood, such as beech.
- Pentsanpolysulfate may be used as a physiologically acceptable salt form, and the physiologically acceptable salts include alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as calcium salt. , And magnesium salts.
- a particularly preferred salt is sodium pentosan polysulfate.
- the pentosan polysulfate is not particularly limited, but one having a weight average molecular weight of 1000 to 30,000 is preferably used, more preferably 2000 to 10000, and even more preferably 4000 to 6500.
- Glucomannan is mainly composed of glucose and mannose, and both are ⁇ (1 ⁇ 4) bonded to form a main chain, and partly branched by ⁇ (1 ⁇ 3) bond or ⁇ (1 ⁇ 6) bond.
- Insulin is a substance in which fructose having terminal glucose is ⁇ (2 ⁇ 1) bound and 2 to 140 molecules are bound.
- Xylooligosaccharide is a hydrolyzate of xylan, and is an oligosaccharide having a structure in which about 2 to 7 xyloses are ⁇ (1 ⁇ 4) bound.
- the above-mentioned polysaccharide may be used as a physiologically acceptable salt form, and examples of the physiologically acceptable salt include alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as calcium salt. And magnesium salts and the like, and a plurality of these salts are also included.
- the above-mentioned polysaccharide can be extracted and recovered from animals, plant tissues, microorganisms such as Streptococcus microorganisms, animal cells, or cultures of plant cells. Moreover, a commercially available product can also be used.
- a medicine effective for reducing nasal polyps which contains the above-mentioned predetermined polysaccharide, preferably a predetermined sulfated polysaccharide as an active ingredient.
- the medicament of the present invention has a nasal polyp reducing effect, diseases presenting nasal polyps, specifically, chronic sinusitis including eosinophil sinusitis and non-eosinophil sinusitis, and chronic sinusitis including non-eosinophil sinusitis, It can also be expected to improve symptoms such as allergic rhinitis.
- nasal polyps also called nasal polyps
- nasal polyps are fleshy growths of the nasal mucosa at the site of lamina basement where subordinate edema occurs (usually around the opening of the maxillary sinus).
- Patients in need of treatment for nasal polyps are those with nasal polyps, specifically those with sinusitis, preferably those with chronic sinusitis.
- Chronic sinusitis includes eosinophilic sinusitis and non-eosinophil sinusitis.
- Treatment of nasal polyps includes ameliorating symptoms such as nasal congestion caused by nasal polyps, reducing nasal polyps, or treating nasal polyps, that is, reducing nasal polyps and improving symptoms such as nasal congestion.
- the improvement of symptoms such as nasal congestion caused by nasal polyps is that clinical symptoms such as nasal congestion are improved as compared with the polysaccharide non-administered group used in the present invention, even if the number and size of nasal polyps are not reduced.
- Means. Shrinkage of nasal polyps means that there is at least one reduction in the number and size of nasal polyps (area and weight per nasal polyp).
- the concentration of the polysaccharide used in the present invention is preferably about 3 ⁇ 10 -7 to 30 w / v%, more preferably about 0.003 to 10 w / v% in the case of a liquid preparation.
- the polysaccharide used in the present invention is used as an intranasal administration preparation delivered into the nasal cavity presenting nasal polyps by intranasal administration.
- the nasal administration preparation is a form of a drug intended for intranasal administration, and specifically, is a liquid preparation, a suspension preparation, a powder preparation, a solid preparation, or a semi-solid preparation.
- Suspensions are liquid formulations containing solid particles dispersed in a liquid medium.
- Preferable dosage forms of intranasal administration preparations include nasal drops.
- Nasal drops are preparations to be administered to the nasal cavity or nasal mucosa, and are classified into nasal drops and nasal powders.
- nasal drops can be sprayed and inhaled, if necessary, using a spraying device having an appropriate spray amount uniformity such as a spray pump.
- the dose of nasal drops can be adjusted by using a spraying device capable of adjusting the amount of spray.
- Nasal drops are liquid nasal drops that are administered to the nasal cavity, or solid nasal drops that are used by dissolving or suspending before use, and usually dissolve or dissolve the active ingredient as it is or by adding a solvent or other appropriate additives. It can be produced by suspending and, if necessary, filtering. Alternatively, an appropriate dissolution solution or suspension solution can be used, and the solution can be dissolved or suspended before use.
- a solubilizing agent, an tonicity agent, a buffering agent, a pH adjusting agent, or the like can be added to the nasal drops.
- a suspending agent, a dispersant, a stabilizer, or the like can be added, if necessary, in order to obtain a uniform state of the active ingredient.
- Dosage forms of nasal drops include, for example, spray nasal drops, nasal aerosols, and nasal nebulizers. Spray nasal drops usually contain a polysaccharide dissolved or suspended in a solution or mixture in a non-pressurized dispenser. Spray nasal drops have the advantages of a small delivery device, convenience and ease of use, and the ability to accurately measure delivery dosages of 25-200 ⁇ L.
- a liquid containing a polysaccharide or a suspending agent can be used as the spray-type nasal spray.
- Another intranasal morphology is the nasal aerosol.
- the nasal aerosol dispenses the drug due to excessive pressure and releases it through the valve.
- the drug is forcibly dispensed by a micropump bucket, but the vial pressure is similar to atmospheric pressure.
- Nasal aerosols have similar advantages to sprays.
- the nasal nebulizer is an administration form using a device that emits a drug into a fine mist by ultrasonic waves.
- nasal drops are to be filled in a multi-dose container, add an appropriate preservative in an amount sufficient to inhibit the growth of microorganisms, if necessary.
- the container used for the nasal drops is usually an airtight container.
- Nasal drops are fine powdered nasal drops that are administered to the nasal cavity, and are usually manufactured by making the active ingredient into moderately fine particles and, if necessary, mixing them with an appropriate additive to make them homogeneous. Can be done.
- the container used for the nasal drop powder is usually a closed container. Moisture proof is added as needed.
- the medicament of the present invention can be a highly viscous liquid or suspension applied to solid, semi-solid or nasal mucosa such as ointments, ointments, creams and gels. , It may be administered by applying it into the nasal cavity. Dosage forms of these nasal drops, ointments, ointments, creams, gels and the like are prepared for each dosage form together with the polysaccharides and pharmaceutically acceptable additives used in the present invention.
- the pharmaceutically acceptable additive used in the medicament of the present invention include additives usually used in the art, that is, pharmaceutical excipients and pharmaceutical carriers as shown below. , These additives can be appropriately used to prepare a pharmaceutical composition suitable for each administration form by a commonly used method.
- the pharmaceutically acceptable additive used in the medicament of the present invention is not particularly limited as long as it is an additive usually used in the art, and for example, a base, a solubilizing agent, an excipient, and a dispersion.
- Agents, emulsifiers, thickeners, tonicity agents, buffers, pH regulators, stabilizers, chelating agents, preservatives, antioxidants, absorption enhancers, moisturizers, fillers, cross-linking agents, refreshing agents And a film agent, and these additives can be appropriately used to prepare a pharmaceutical composition suitable for each administration form by a commonly used method.
- Examples of the base used in the medicament of the present invention include a hydrophobic base, a hydrophilic base and water.
- the hydrophobic base is not particularly limited, but higher hydrocarbons, fats and oils, waxes, fatty acids, higher alcohols, fatty acid esters and the like can be used.
- Examples of higher hydrocarbons include squalane, synthetic paraffin, liquid paraffin, white petrolatum, microcrystalline wax and the like.
- Examples of fats and oils include sesame oil, corn oil, olive oil and cacao fat.
- Examples of waxes include beeswax, beeswax, lanolin, reduced lanolin, and selecin wax.
- Examples of fatty acids include stearic acid and oleic acid.
- Examples of the higher alcohol include lanolin alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, cetostearyl alcohol and cholesterol.
- Examples of fatty acid esters include isopropyl myristate, stearyl myristate, and medium-chain fatty acid triglycerides.
- Examples of the hydrophilic base include ethanol, propanol, isopropanol, butanol, isobutanol, propylene glycol, polyethylene glycol and macrogol.
- the solubilizing agent is not particularly limited, and examples thereof include propylene glycol, D-mannitol, benzyl benzoate, ethanol, isopropanol, triethanolamine, sodium carbonate, sodium citrate, and the like.
- Excipients are not particularly limited, but include, for example, sugar alcohols such as erythritol, martitol, mannitol, sorbitol, xylitol and lactitol, sucrose, lactose, reduced maltose water candy, powdered reduced maltose water candy, glucose and maltose.
- sugar alcohols such as erythritol, martitol, mannitol, sorbitol, xylitol and lactitol
- sucrose, lactose reduced maltose water candy, powdered reduced maltose water candy, glucose and maltose.
- examples thereof include sugars, corn starch, crystalline cellulose, calcium monohydrogen phosphate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, light anhydrous silicic acid, hydrous silicon dioxide and silicon dioxide.
- a dispersant is used as an additive, if desired.
- the dispersant is not particularly limited, and is, for example, celluloses such as methyl cellulose, sodium carboxymethyl cellulose and hydroxypropyl methyl cellulose, synthetic polymer compounds such as polyvinyl alcohol, polyvinylpyrrolidone and carboxyvinyl polymer, polyoxyethylene alkyl ether and polyoxy.
- the emulsifier examples include cationic surfactants, anionic surfactants, amphoteric surfactants and nonionic surfactants.
- the cationic surfactant is not particularly limited, and examples thereof include cetyltrimethylammonium chloride, lauryldimethylbenzylammonium chloride, tetrabutylammonium chloride, and dioctadecyldimethylammonium chloride.
- the anionic surfactant is not particularly limited, and examples thereof include sodium alkylbenzene sulfonate, sodium dodecyl sulfate, sodium coconut alcohol ethoxysulfate, sodium ⁇ -olefin sulfonate, and emulsified cetostearyl alcohol.
- the nonionic surfactant is not particularly limited, and is, for example, polyoxyethylene alkyl ether, polyoxyethylene alkyl phenol ether, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyl stearate, glycerin fatty acid ester, and the like. Examples include diglycerin fatty acid ester.
- amphoteric tenside is not particularly limited, and examples thereof include N-alkyl-N, N-dimethylammonium betaine and imidazoline type amphoteric tenside.
- the above surfactants can be used alone or in combination.
- the viscous agent is not particularly limited, and examples thereof include sodium alginate, gelatin, methyl cellulose, carboxyvinyl polymer, carboxymethyl cellulose, and sodium polyacrylate.
- the tonicity agent is not particularly limited, and examples thereof include saccharides such as sorbitol, glucose and mannitol, polyhydric alcohols such as glycerin, polyethylene glycol and propylene glycol, and inorganic salts such as sodium chloride and potassium chloride. ..
- the buffer is not particularly limited, and examples thereof include boric acid, borax, sodium monohydrogen phosphate, sodium dihydrogen phosphate, citric acid, sodium citrate, sodium dihydrogen citrate, and disodium citrate.
- the pH regulator is not particularly limited, but for example, diisopropanolamine, triisopropanolamine, triethanolamine, potassium hydroxide, sodium hydroxide, sodium citrate, phosphoric acid, tartaric acid, dl-malic acid, glacial acetic acid and the like. Can be mentioned.
- the stabilizer is not particularly limited, and examples thereof include sodium edetate, sodium oleate, casein, and sodium casein salt.
- the chelating agent is not particularly limited, and examples thereof include edetic acid, oxalic acid, citric acid, pyrophosphate, hexametaphosphate, gluconic acid, and salts thereof.
- the preservative is not particularly limited, but for example, quaternary ammonium salts such as benzalkonium chloride, benzoxoneium chloride, benzododecinium bromide, benzethonium chloride, cetylpyridinium chloride and cetrimid, benzoic acid and salts thereof, acceptable hydroxy C 1 -C 7 alkyl esters and salts of benzoic acid 4-hydroxybenzoic acid, such as methyl and propyl 4-hydroxybenzoate, chlorhexidine digluconate, chlorhexidine and its intranasal such chlorhexidine acetate and chlorhexidine chloride Examples thereof include salts that can be used, 2-phenylethanol, 2-phenoxyethanol, chlorobutanol and sorbic acid.
- quaternary ammonium salts such as benzalkonium chloride, benzoxoneium chloride, benzododecinium bromide, benzethonium chloride, cetylpyridinium chloride and ce
- the antioxidant is not particularly limited, and examples thereof include polyphenol, ascorbic acid, t-butylhydroquinone, butylhydroxyanisole, butylhydroxytoluene, L-cysteine hydrochloride, sodium bisulfite, ⁇ -tocopherol and its derivatives. ..
- the absorption enhancer is not particularly limited, and for example, diisopropyl adipate, lecithin, squalane, squalene, l-menthol, polyethylene glycol, isopropyl myristate, dimethyl sulfoxide, peppermint oil, eucalyptus oil, d-limonene and dl-limonene and the like. Can be mentioned.
- the moisturizer is not particularly limited, and examples thereof include glycerin, propylene glycol, and 1,3-butylene glycol.
- the filler is not particularly limited, and examples thereof include kaolin, titanium dioxide, and zinc oxide.
- the cross-linking agent is not particularly limited, and examples thereof include acetaldehyde, dimethyl ketone, and aluminum sulfate.
- the refreshing agent is not particularly limited, and examples thereof include l-menthol, dl-camphor, d-borneol, fennel oil, peppermint oil, and peppermint water.
- the nasal drops containing the medicament of the present invention may contain an acceptable film agent in the nose.
- an acceptable film agent in the nose.
- the coating agent is not particularly limited, and is, for example, a water-soluble or swellable cellulose material such as hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl methyl cellulose and sodium carboxymethyl cellulose, polyvinylpyrrolidone (povidone) and crosslinked polyvinyl. Pyrrolidone (crosspovidone) can be mentioned.
- the medicament of the present invention varies depending on the age, weight, sex, degree (amount, range) of nasal polyps, etc. of the patient, and is not particularly limited, and the applied amount varies depending on the degree of nasal polyps. In the nasal cavity, 5 ⁇ 10-11 to 1 g per day is applied once to several times.
- the medicament of the present invention can be used for asthma treatment for patients with chronic sinusitis who also have asthma. It can also be administered in combination with drugs.
- the asthma therapeutic agent include the following agents.
- Inhaled steroids or nasal spray steroids beclomethasone propionate, fluticasone propionate, budesonide, ciclesonide, mometasone furancarboxylic acid ester, etc.;
- Combination of inhaled corticosteroids and long-acting ⁇ 2-agonists combination with salmeterol xinafoate, combination with formoterol fumarate hydrate;
- Theophylline sustained-release preparations Theophylline, Theorong, Slowbid, Unifil, Unicon, Neophyllin, Theophylline, etc .
- Short-acting theophylline drugs neophyllin, theophylline, monophyllin, astomoridin D / M, astophyllin, albina suppositories, etc.
- Long-acting ⁇ 2-agonist Inhalant (LABA) / Celevent, patch / Hokunarin tape, Oral drug / Meptin, Spiropent,
- Mediator release inhibitors Intal, Rezaben, Solfa, Romet, Ketotifen, Allegisal, Pemilaston, Tazanol, Tazarest, etc.; Thromboxane A2 inhibitor: Vega, Domenan, etc .; Thromboxane A2 antagonists: Bronica, Vinas, etc .; Oral steroids: prednisolone, prednisolone, medrol, linderon, redacoat, decadron, corson, dexamethasone, paramaison, etc.; Immunosuppressive drugs: cyclosporine, etc .; Interleukin 4R (IL-4R) inhibitor: dupyrimab, etc .; Iodine preparation: Ioletin, etc.
- IL-4R Interleukin 4R
- the drug of the present invention can be administered in combination with a vasoconstrictor.
- vasoconstrictor include naphazoline hydrochloride, tetrahydrozoline hydrochloride, phenylephrine hydrochloride, epinephrine hydrochloride, dl-methylephedrine hydrochloride, tetrahydrozoline nitrate, naphazoline nitrate, and epinephrine.
- Example 1 Nasal polyp-reducing action of a heparinoid on nasal polyps in patients with eosinusitis
- Eosinophilic sinusitis Reduced pressure-dried heparinoids (organic sulfate groups 25.8 to 37.3% w / w, D-glucuronic acid 19.0 to 24.0% w) / W, Maruho Co., Ltd.) was dissolved in physiological saline to prepare heparinoid solutions (0.3, 30 and 3000 ⁇ g / mL).
- a nasal polyp sample removed from a patient with eosinophil sinusitis was cut into small pieces of about 5 mm square, and the water was wiped off and the weight was measured.
- Each sample was transferred to a 12-well plate, 1 mL of saline or a heparinoid solution of each concentration was added, and the mixture was incubated at 37 ° C for about 24 hours. The sample was taken out from the plate, the water was wiped off, and the weight was measured. The difference in sample weight before and after incubation was evaluated as an index of nasal polyp reduction effect. The number of cases in the physiological saline group and the heparinoid solution group at each concentration in FIG. 1 was 6.
- Figure 1 shows the change in sample weight before and after incubation. * And ** in FIG. 1 show significant differences in nasal polyp weight before and after incubation by paired t-test (* P ⁇ 0.05, ** P ⁇ 0.01). Incubation with saline did not show a significant change in nasal polyp weight, whereas incubation with heparinoid solution (0.3, 30 and 3000 ⁇ g / mL) significantly reduced nasal polyp weight. From this, it was suggested that heparinoids have a nasal polyp reducing effect.
- Example 2 Nasal polyp-reducing effect of heparinoid on nasal polyps of patients with eosinophil sinusitis 0.003, 0.03, 0.3 and 30 ⁇ g / mL heparinoid-reducing effect of heparinoid solution by the same method as in Example 1. was evaluated. The number of cases in the physiological saline group and the heparinoid solution group at each concentration in FIG. 2 was 6.
- Figure 2 shows the change in sample weight before and after incubation. ** in FIG. 2 indicates a significant difference in nasal polyp weight before and after incubation by paired t-test (** P ⁇ 0.01). Incubation with saline did not show a significant change in nasal polyp weight, whereas incubation with heparinoid solutions (0.003, 0.03, 0.3 and 30 ⁇ g / mL) significantly reduced nasal polyp weight. This suggests that heparinoids have a nasal polyp-reducing effect.
- Example 3 Nasal polyp reducing action of pentosan polysulfate (PPS) on nasal polyps of patients with eosinophil sinusitis
- PPS pentosan polysulfate
- a PPS solution (0.003 ⁇ g / mL) was prepared by the same method as in Example 1 to reduce nasal polyps.
- PPS sodium pentosan polysulfate manufactured by Molclone Labs (weight average molecular weight 4000 to 6500, sulfur content 13.0 to 20.0% w / w, glucuronic acid content 2.5 to 4.0% w / w) was used. used.
- the number of cases in the physiological saline group and the PPS solution group in FIG. 3 was 6.
- Figure 3 shows the change in sample weight before and after incubation. Incubation with saline showed almost no decrease in nasal polyp weight, whereas incubation with PPS solution (0.003 ⁇ g / mL) significantly reduced nasal polyp weight, indicating that PPS is eosinophil. It was suggested that it has a nasal polyp reducing effect in patients with sinusitis.
- Example 4 Nasal polyp reduction effect of each polysaccharide on nasal polyps of patients with eosinophil sinusitis
- the following 11 types of polysaccharide solutions 300 ⁇ g / mL and gluco, respectively, except for glucomannan.
- 30 ⁇ g / mL of mannan was prepared and the nasal polyp reducing effect was evaluated.
- the number of examples of the physiological saline group and each polysaccharide solution group in Tables 1 to 4 was set to 1 example.
- Chondroitin was synthesized by desulfurizing sodium chondroitin sulfate (manufactured by Bioiberica) by the same method as in Japanese Patent Application Laid-Open No. 07-062001. Low-molecular-weight chondroitin sulfate was synthesized by hydrolyzing sodium chondroitin sulfate (manufactured by Bioiberica) under acidic conditions. For other polysaccharides, the commercially available products described were used.
- Tables 1 to 4 show changes in sample weight before and after incubation. Incubation with physiological saline showed almost no reduction in nasal polyp weight, whereas incubation with 11 types of polysaccharide solutions (300 ⁇ g / mL for each other than glucomannan and 30 ⁇ g / mL for glucomannan) resulted in nasal polyps. The significant weight loss suggests that the 11 polysaccharides have a nasal polyp-reducing effect in patients with eosinophilia sinusitis.
- Example 5 Nasal polyp reducing effect of heparinoid and PPS on nasal polyps of patients with non-eosinophil sinusitis
- Heparinoid solution and PPS solution (0.03, 0.3, 30 and 300 ⁇ g, respectively) by the same method as in Example 1. / mL) was prepared and the effect of reducing nasal polyps on nasal polyp samples removed from patients with non-eosinophil sinusitis was evaluated.
- the heparinoids and PPS used were the same as those used in Examples 1 and 3.
- the number of examples in the physiological saline group, heparinoid solution, and PPS solution group in Table 5 was one.
- Table 5 shows the change in sample weight before and after incubation. Incubation with saline did not reduce nasal polyp weight, whereas incubation with heparinoid solution and PPS solution (0.03, 0.3, 30 and 300 ⁇ g / mL, respectively) significantly reduced nasal polyp weight. Therefore, it was suggested that heparinoids and PPS also have a reducing effect on nasal polyps in patients with non-eosinophil sinusitis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
鼻茸の成因については、血管透過性の亢進による浮腫、粘膜固有層脱出、細胞外マトリックスの蓄積等さまざまな成因が考えられており、さらに、種々のサイトカインや増殖因子との関連も報告されている。増殖因子としては、血管内皮増殖因子や血小板由来増殖因子と鼻茸との関連が報告されている(非特許文献1:川崎医学会誌 35(1):39-50,2009)。
慢性副鼻腔炎のうち、鼻茸を伴う疾患には、好酸球性副鼻腔炎と非好酸球性副鼻腔炎がある。そのうち好酸球性副鼻腔炎は、指定難病であり、両側の多発性鼻茸と粘調な鼻汁により、高度の鼻閉と嗅覚障害示す、成人発症の難治性副鼻腔炎である。当該疾患の治療には、抗菌薬は無効であり、ステロイドの内服にのみ反応する。鼻腔内に鼻茸が充満しているため、鼻副鼻腔手術で鼻茸の摘出を行うが、すぐに再発するという問題があった。
一方、抗凝固作用を有するヘパリンは、ラット鼻粘膜炎症モデルにおいて粘液産生や好中球浸潤に対し有意に抑制したことが報告されているが(非特許文献4:耳鼻免疫アレルギー 29(3):221-227, 2011)、好酸球性副鼻腔炎患者から採取した鼻茸に対しては縮小効果を示さなかった(非特許文献5:Allergology International 66(2017) 594-602)。
(1) 多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、デルマタン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、イヌリン、およびキシロオリゴ糖から選択される多糖又はその塩を有効成分とする鼻茸縮小剤。
(1a) 前記多糖またはその塩が、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、およびイヌリンから選択される、(1)に記載の鼻茸縮小剤。
(1b) 硫酸化多糖又はその塩を有効成分とする鼻茸縮小剤。
(1c) 前記硫酸化多糖又はその塩が、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、およびペントサンポリ硫酸から選択される、(1b)に記載の鼻茸縮小剤。
(2) 前記硫酸化多糖が、D-ガラクトサミン、D-グルクロン酸、L-イズロン酸、D-グルコース、D-ガラクトース、D-キシロース、及びL-アラビノースから選択さ
れる単糖から構成され、前記単糖は一部アセチル化されていてもよい、(1b)に記載の鼻茸縮小剤。
(3) 前記硫酸化多糖が、多硫酸化コンドロイチン硫酸、多硫酸化デルマタン硫酸、又はペントサンポリ硫酸である、(1b)又は(2)に記載の鼻茸縮小剤。
(4) 鼻腔内投与される、(1)~(3)のいずれか一項に記載の鼻茸縮小剤。
(5) 慢性副鼻腔炎患者の鼻茸の縮小に用いられる、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、デルマタン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、イヌリン、およびキシロオリゴ糖から選択される多糖又はその塩を含む医薬組成物。
(5a) 前記多糖が、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、およびイヌリンから選択される、(5)に記載の医薬組成物。
(5b) 慢性副鼻腔炎患者の鼻茸の縮小に用いられる硫酸化多糖又はその塩を含む医薬組成物。
(6) 前記硫酸化多糖が、D-ガラクトサミン、D-グルクロン酸、L-イズロン酸、D-グルコース、D-ガラクトース、D-キシロース、及びL-アラビノースから選択される単糖から構成され、前記単糖は一部アセチル化されていてもよい、(5b)に記載の医薬組成物。
(7) 前記硫酸化多糖が、多硫酸化コンドロイチン硫酸、多硫酸化デルマタン硫酸、又はペントサンポリ硫酸である、(5b)又は(6)に記載の医薬組成物。
(8) 前記慢性副鼻腔炎患者が、好酸球性副鼻腔炎又は非好酸球性副鼻腔炎患者である、(5)~(7)のいずれか一項に記載の医薬組成物。
(9) 前記慢性副鼻腔炎患者が、好酸球性副鼻腔炎患者である、(5)~(8)のいずれか一項に記載の医薬組成物。
(10) (5)~(9)のいずれか一項に記載の医薬組成物を含む鼻腔内投与製剤。
(11) 鼻茸の治療を必要とする患者に、有効量の多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、デルマタン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、イヌリン、およびキシロオリゴ糖から選択される多糖又はその塩を投与することによる、鼻茸を処置する方法。
(12) 前記多糖またはその塩が、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、およびイヌリンから選択される、(11)に記載の方法。
(13) 鼻茸の治療を必要とする患者に、有効量の硫酸化多糖又はその塩を投与することを含む、鼻茸の縮小方法。
(14) 前記硫酸化多糖又はその塩が、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、およびペントサンポリ硫酸から選択される、(13)に記載の方法。
(15) 前記硫酸化多糖が、D-ガラクトサミン、D-グルクロン酸、L-イズロン酸、D-グルコース、D-ガラクトース、D-キシロース、及びL-アラビノースから選択される単糖から構成され、前記単糖は一部アセチル化されていてもよい、(13)に記載の方法。
(16) 前記硫酸化多糖が、多硫酸化コンドロイチン硫酸、多硫酸化デルマタン硫酸、又はペントサンポリ硫酸である、(13)に記載の方法。
(17) 前記患者が、副鼻腔炎に罹患している、(11)に記載の方法。
(18) 前記患者が、好酸球性副鼻腔炎又は非好酸球性副鼻腔炎の慢性副鼻腔炎に罹患している、(11)に記載の方法。
(19) 前記患者が、好酸球性副鼻腔炎に罹患している、(11)に記載の方法。
(20) 鼻腔内投与する、(11)に記載の方法。
本発明で用いられる多糖は、コンドロイチン硫酸、コンドロイチン、デルマタン硫酸、ケラタン硫酸、ヘパラン硫酸、および多硫酸化コンドロイチン硫酸などの多硫酸化ムコ多糖から選択される硫酸化ムコ多糖、硫酸化ムコ多糖に、さらにデキストラン硫酸およびペントサンポリ硫酸を含めた硫酸化多糖、ならびに、グルコマンナン、イヌリン、およびキシロオリゴ糖から選択される多糖である。好ましくは、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、およびイヌリンから選択される多糖である。
本発明における硫酸化多糖は、D-グルコサミン、D-ガラクトサミン、D-グルクロン酸、L-イズロン酸、D-ガラクツロン酸、D-グルコース、D-ガラクトース、D-キシロース、及びL-アラビノースから選択される単糖から構成され、これらの単糖は一部アセチル化されていてもよく、該単糖の1種又は2種以上を繰り返し単位とする多糖に硫酸基を有するものである。本発明で用いられる硫酸化多糖は、硫酸基が、単糖1分子当たり平均0.55~4分子、好ましくは、平均0.6~2.9分子、より好ましくは平均0.7~2分子である。
また、本発明で用いられる硫酸化多糖の硫酸基含有量は、日本薬局方外医薬品規格2002の「ヘパリン類似物質」に規定された定量法による有機硫酸基含有量が10~70w/w%であるものが好ましく、より好ましくは10~65w/w%の有機硫酸基含有量を有する硫酸化多糖である。
好ましくは、構成する主な単糖が、D-ガラクトサミン、D-グルクロン酸、L-イズロン酸、D-グルコース、D-ガラクトース、D-キシロース及びL-アラビノースから選択され、当該単糖は一部アセチル化されていてもよい、硫酸化多糖である。より好ましくは、D-ガラクトサミン、D-グルクロン酸、D-グルコース、D-ガラクトース、D-キシロース及びL-アラビノースから選択される単糖から構成される硫酸化多糖である。
なお、一部アセチル化されている単糖としては、例えば天然に存在する単糖として、アセチルグルコース、N-アセチルグルコサミン、アセチルガラクトース、N-アセチルガラクトサミン、アセチルキシロース等が挙げられる。
本発明で用いられる硫酸化多糖もしくはその塩の重量平均分子量は、1000~10000000程度であり、好ましくは、4000~1000000程度である。
本明細書で用いられる重量平均分子量とは、Miの分子量を持つ高分子がNi個存在する場合、以下の計算式
重量平均分子量(Mw)=Σ(Ni・Mi2)/Σ(Ni・Mi)
で表される値である。
硫酸化多糖は、一部アセチル化されていてもよい単糖から構成される多糖に、硫酸化反応を行い硫酸基を導入することにより得られる。
硫酸化反応は、原料の多糖1gに対し、氷冷した溶媒を10~30mL用意し、これに硫酸化剤を原料多糖1gに対して2~6倍を加え、この溶液に、原料の多糖1gを加え、0℃~100℃で、1~10時間反応させて、硫酸化を行う。使用する溶媒としては、ピリジン、N,N-ジメチルホルムアミド、N,N-ジアルキルアクリルアミド等が使用でき、硫酸化剤としては、クロロスルホン酸、トリエチルアミン-サルファトリオキサイド錯塩等が使用できる。
本発明に用いられる一部アセチル化されていてもよい単糖から構成される硫酸化多糖は、好ましくは当該硫酸化多糖の構成糖の0%~60%(モル比)が、N-アセチル化またはO-アセチル化されている。
本願明細書において、コンドロイチン硫酸、コンドロイチン、デルマタン硫酸、ケラタン硫酸およびヘパラン硫酸、および多硫酸化コンドロイチン硫酸などの多硫酸化ムコ多糖は、硫酸化ムコ多糖に分類される。
また、グルコマンナン、イヌリン、およびキシロオリゴ糖は、上記に該当しない多糖に分類される。
「硫酸化ムコ多糖」とは、硫酸基を有するムコ多糖を意味する。本発明の硫酸化ムコ多糖には、糖鎖中に硫酸基を持つ天然由来のムコ多糖、ムコ多糖や天然の硫酸化ムコ多糖をさらに化学的に修飾したものも包含される。
「多硫酸化ムコ多糖」は、硫酸化ムコ多糖のうち、糖鎖中に硫酸基をより多く有するもので、天然由来の多硫酸化ムコ多糖に加え、ムコ多糖や天然の硫酸化ムコ多糖をさらに化学的に硫酸化したものも包含される。
硫酸化ムコ多糖の例について以下に説明するが、その全体構造は、これらの硫酸化ムコ多糖が形成するプロテオグリカンの種類、これらの硫酸化ムコ多糖が存在する動物種、組織、発生段階等により、多様性を有する。すなわち、天然由来のムコ多糖または硫酸化ムコ多糖は、これらの硫酸化ムコ多糖の基本構造として以下に説明する構造にさらに修飾を受けたり、その一部に基本構造以外の構造や糖を有する場合もある。本発明に用いられるこれらの各硫酸化ムコ多糖には、そのようなバリエーションも含まれる。
「コンドロイチン硫酸」は、動物の粘質性分泌液や軟骨組織などから分離される物質である。構成糖と硫酸基の結合位置により、コンドロイチン硫酸A、およびコンドロイチン硫酸C、D、Eなどがあるが、本願明細書においては、コンドロイチン硫酸A、およびコンドロイチン硫酸Cは硫酸化ムコ多糖として、コンドロイチン硫酸DおよびEは多硫酸化ムコ多糖としても分類される硫酸化ムコ多糖である。
コンドロイチン硫酸A(コンドロイチン4硫酸)は、4位に硫酸基を持つN-アセチル-D-ガラクトサミン(GalNAc)とD-グルクロン酸(GlcA)の二糖の繰り返し構造を基本構造として有する。
コンドロイチン硫酸C(コンドロイチン6硫酸)は、6位に硫酸基を持つGalNAcとGlcAの二糖の繰り返し構造を基本構造として有する。
好ましくは、コンドロイチン硫酸AおよびCである。
また、コンドロイチン硫酸を重量平均分子量が10万以下、好ましくは1万~5万の低分子化した低分子コンドロイチン硫酸も用いることができる。低分子コンドロイチン硫酸は、コンドロイチナーゼまたはコンドロイチン硫酸リアーゼなどの酵素を用いて天然のコンドロイチン硫酸を分解することにより得られる。
「デルマタン硫酸」は、イズロン酸(IdoUA)とGalNAcの繰り返し二糖からなり、GalNAcの4位に硫酸基を有する構造を基本構造とする。コンドロイチン硫酸Bと称されることもある。
「ケラタン硫酸」は、ガラクトース(Gal)およびN-アセチル-D-グルコサミン(GlcNAc)がそれぞれβ(1→4)およびβ(1→3)結合で交互に結合した繰り返し二糖からなり、GlcNAcの6位は常に硫酸化された構造を基本構造とする。
「ヘパラン硫酸」は、D-グルコサミン、D-グルクロン酸、L-イズロン酸を構成糖とする多糖のN-アセチル、N-硫酸、O-硫酸置換体である。
「コンドロイチン」は、GalNAcとGlcAの繰り返し二糖を基本構造とし、硫酸基が特に少ない(通常、二糖単位当たり0.7分子以下)ムコ多糖である。ウシ角膜など天然由来のほかに、コンドロイチン硫酸を化学的に脱硫酸化しても得られる。
また、本発明で用いられる硫酸化ムコ多糖類には、コンドロイチン硫酸、デルマタン硫酸、ケラタン硫酸などがさらに硫酸化された多硫酸化ムコ多糖も含まれる。
コンドロイチン硫酸AやCなどの硫酸化ムコ多糖にさらに硫酸基を導入し多硫酸化ムコ多糖を得る方法としては、既知の方法、例えば、硫酸化剤存在下で適当な溶媒中で加温し、反応させる方法が挙げられる。硫酸化剤としては、多硫酸化の目的を達成することができるものであれば特に限定されるものではないが、無水硫酸とピリジン若しくはトリエチルアミン等の錯体を使用するのが好ましい。硫酸化剤の使用割合は、所望の硫酸化ムコ多糖の硫酸化率(又は硫黄含有率)及び反応条件に従って任意に選択することができるが、一般に、多硫酸化する硫酸化ムコ多糖1重量部に対して2~10重量部となるような割合で使用する。溶媒としては、例えば、ジメチルホルムアミド等の親プロトン性溶媒を挙げることができる。反応温度、反応時間としては、所望の硫酸化率が達成できる限り特に限定されないが、例えば、40~90℃で30分~20日間程度反応させる。
多硫酸化コンドロイチン硫酸としては、例えば、コンドロイチン硫酸D、コンドロイチン硫酸E、日本薬局方外医薬品規格に記載のヘパリン類似物質が挙げられる。好ましくは、日本薬局方外医薬品規格に記載のヘパリン類似物質である。
具体的には、物理化学的性質として次の値を示す多硫酸化コンドロイチン硫酸である。
a)硫酸基含量:25.8~37.3%
b)極限粘度:0.09~0.18
コンドロイチン硫酸E(コンドロイチン4,6硫酸)はスルメイカ軟骨等から単離され、コンドロイチン硫酸Cに似た構造を持ち、その基本構造は、GalNAcの4および6位に硫酸基を有する。
「多硫酸化デルマタン硫酸」とは、N-アセチルガラクトサミンとL-イズロン酸からなる繰り返し糖単位をもつ天然の硫酸化ムコ多糖であるデルマタン硫酸に、化学的に硫酸基を導入することによって合成されたものおよび天然に存在するデルマタンポリ硫酸、またはこれに化学的に硫酸基を導入することによって合成されたものを意味する。
本発明に用いられる上記以外の硫酸化多糖について、以下に説明する。
「デキストラン硫酸」は、グルコースがα(1→6)結合した直鎖と、α(1→3)結合の分枝から始まる通常1000ないし数千ダルトン(Da)から数十万Daまでの様々な長さの鎖で構成されるグルコース単位からなる多糖であるデキストランのポリアニオン誘導体であり、C2~C4位ならびに末端基のC1位およびC6位の一部が硫酸化されている。
「ペントサンポリ硫酸」はD-キシロース及び/又はL-アラビノースを構成単糖とする多価陰イオン性多糖の混合物を含む、半合成硫酸化多糖である。ペントサンポリ硫酸は、木本、例えばブナから得られる多糖(例えばキシラン)の化学的硫酸化により生成される。一般に、キシラン鎖に側鎖としてO-メチルグルクロン酸が結合したものの多硫酸化体と考えられている。
ペントサンポリ硫酸は、生理学的に許容される塩形態として用いられてもよく、生理学的に許容される塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、カルシウム塩等のアルカリ土類金属塩、及びマグネシウム塩が挙げられる。特に好ましい塩は、ペントサンポリ硫酸ナトリウムである。
ペントサンポリ硫酸としては、特に限定されないが、重量平均分子量が、1000~30000のものを用いることが好ましく、より好ましくは2000~10000であり、4000~6500のものを用いることがさらに好ましい。
以下に、硫酸化多糖以外の多糖の具体例について説明する。
「グルコマンナン」は、主にグルコースとマンノースからなり、両者がβ(1→4)結合して主鎖を形成し、一部β(1→3)結合やβ(1→6)結合による枝分かれ構造を有する。
「イヌリン」は、末端グルコースを持つフルクトースがβ(2→1)結合し2~140分子結合した物質である。
「キシロオリゴ糖」は、キシランの加水分解物であり、キシロースが2~7個程度β(1→4)結合した構造を持つオリゴ糖である。原料であるキシランに由来して、4-O-メチルグルクロン酸側鎖、アラビノフラノシル側鎖等を有するものも含まれる。
上記多糖は、生理学的に許容される塩形態として用いられてもよく、生理学的に許容される塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、カルシウム塩等のアルカリ土類金属塩、及びマグネシウム塩等が挙げられ、これらの複数塩も含まれる。
上記多糖は、動物や植物組織、ストレプトコッカス属微生物等の微生物、動物細胞もしくは植物細胞の培養物から抽出、回収することができる。また、市販品を用いることもできる。
また、本発明の医薬は、鼻茸の縮小効果を有することから、鼻茸を呈する疾患、具体的には好酸球性副鼻腔炎や非好酸球性副鼻腔炎を含む慢性副鼻腔炎や、アレルギー性鼻炎等の症状改善も期待できる。
また、本発明の別の態様は、鼻茸の治療を必要とする患者に、本発明で用いられる所定の多糖を投与することによる、鼻茸を処置する方法、鼻茸を縮小する方法、または鼻茸の予防または治療方法を提供する。
鼻茸は、鼻ポリープとも称され、粘膜固有層に就下性の浮腫が起きる部位(通常は上顎洞開口部の周囲)にできる鼻粘膜の肉質の増殖である。鼻茸の治療を必要とする患者は、鼻茸を伴う疾患、具体的には、副鼻腔炎患者、好ましくは慢性副鼻腔炎に罹患している患者である。慢性副鼻腔炎には、好酸球性副鼻腔炎と非好酸球性副鼻腔炎が含まれる。
鼻茸を処置とは、鼻茸による鼻閉等の症状を改善すること、鼻茸を縮小すること、または鼻茸の治療、すなわち、鼻茸の縮小と鼻閉等の症状の改善、が含まれる。
鼻茸による鼻閉等の症状の改善は、鼻茸の数や大きさに減少が見られなくても、鼻閉などの臨床症状が、本発明に用いられる多糖の非投与群に比べて改善することを意味する。
鼻茸の縮小は、鼻茸の数の減少や大きさ(鼻茸1つあたりの面積や重量)の縮小の少なくとも1つがみられることを意味する。
鼻腔内投与製剤は、鼻腔内投与を目的とした薬物の形態であり、具体的には、液剤、懸濁剤、粉末剤、固形剤又は半固形剤である。懸濁剤は、液体媒体中に分散された固体粒子を含有する液体製剤である。
鼻腔内投与製剤の好ましい剤形としては、点鼻剤が挙げられる。
点鼻剤は、鼻腔又は鼻粘膜に投与する製剤であり、点鼻液剤及び点鼻粉末剤に分類される。点鼻剤は、必要に応じて、スプレーポンプなどの適切な噴霧量の均一性を有する噴霧用の器具を用いて噴霧吸入することができる。噴霧量を調節することができる噴霧用の器具を用いることにより、点鼻剤の投与量を調節することができる。
点鼻液剤は、鼻腔に投与する液状、又は用時溶解若しくは用時懸濁して用いる固形の点鼻剤であり、通例、有効成分をそのまま又は溶剤若しくはそのほかの適切な添加剤を加え、溶解又は懸濁し、必要に応じて、ろ過することにより製造することができる。あるいは、適切な溶解液又は懸濁用液を用い、用時溶解又は用時懸濁して用いることができる。点鼻液剤には、必要に応じて、溶解補助剤、等張化剤、緩衝剤又は、pH調節剤などを加えることができる。また、懸濁剤の場合には、有効成分の均一な状態を得るために、必要に応じて、分散剤又は安定化剤などを加えることができる。
点鼻液剤の投与形態としては、例えば、スプレー式点鼻薬、鼻エアロゾル、または鼻ネブライザーが挙げられる。スプレー式点鼻薬は、通常、非加圧ディスペンサー中の溶液又は混合物中に溶解又は懸濁された多糖を含有する。スプレー式点鼻薬は、送達デバイスが小型であり、簡便かつ、使用方法が簡便であり、25~200μLの送達投薬量を正確に計量できる利点を有する。スプレー式点鼻薬には、多糖を含む液体又は懸濁剤を用いることができる。別の鼻腔内形態は、鼻エアロゾルである。鼻エアロゾルは、薬剤を過剰な圧に起因して分注され、バルブを通過して放出する。スプレー式点鼻薬では、薬剤はミクロポンプバケットにより強制的に分注されるが、バイアルの圧は大気圧と同様である。鼻エアロゾルは、スプレーと同様な利点を有する。
鼻ネブライザーは、薬剤を超音波によって細かい霧状にして放出する機器を用いた投与形態である。
点鼻粉末剤は、鼻腔に投与する微粉状の点鼻剤であり、通例、有効成分を適度に微細な粒子とし、必要ならば適切な添加剤と混和し、均質とすることにより製造することができる。点鼻粉末剤に用いる容器は、通例、密閉容器である。必要に応じて、防湿性を付与する。
これらの点鼻剤、軟膏剤、硬膏剤、クリーム剤、ゲル剤等の剤型は、本発明に用いられる多糖及び薬学的に許容される添加剤と共に各剤型に調製される。
本発明の医薬に用いられる薬学的に許容される添加剤としては、当分野において通常用いられている添加剤、即ち、以下に示されるような薬剤用賦形剤や薬剤用担体等があげられ、これらの添加剤を適宜用いて、通常使用されている方法によってそれぞれの投与形態に適切な医薬組成物を調製することができる。
疎水性基剤としては、特に限定されないが、高級炭化水素、油脂類、ロウ類、脂肪酸、高級アルコール及び脂肪酸エステル類などを用いることができる。高級炭化水素としては、例えば、スクワラン、合成パラフィン、流動パラフィン、白色ワセリン及びマイクロクリスタリンワックスなどが挙げられる。油脂類としては、例えば、ゴマ油、トウモロコシ油、オリーブ油及びカカオ脂などが挙げられる。ロウ類としては、例えば、ミツロウ、サラシミツロウ、ラノリン、還元ラノリン及びセレシンロウなどが挙げられる。脂肪酸としては、例えば、ステアリン酸及びオレイン酸などが挙げられる。高級アルコールとしては、例えば、ラノリンアルコール、ミリスチルアルコール、セチルアルコール、ステアリルアルコール、セトステアリルアルコール及びコレステロールなどが挙げられる。脂肪酸エステル類としては、例えば、ミリスチン酸イソプロピル、ミリスチン酸ステアリル及び中鎖脂肪酸トリグリセリドなどが挙げられる。
親水性基剤としては、例えば、エタノール、プロパノール、イソプロパノール、ブタノール、イソブタノール、プロピレングリコール、ポリエチレングリコール及びマクロゴールなどが挙げられる。
溶解補助剤としては、特に限定されないが、例えば、プロピレングリコール、D-マンニトール、安息香酸ベンジル、エタノール、イソプロパノール、トリエタノールアミン、炭酸ナトリウム及びクエン酸ナトリウムなどが挙げられる。
賦形剤としては、特に限定されないが、例えば、エリスリトール、マルチトール、マンニトール、ソルビトール、キシリトール及びラクチトールなどの糖アルコール、白糖、乳糖、還元麦芽糖水アメ、粉末還元麦芽糖水アメ、ブドウ糖及び麦芽糖などの糖類、コーンスターチ、結晶セルロース、リン酸一水素カルシウム、リン酸水素カルシウム、無水リン酸水素カルシウム、軽質無水ケイ酸、含水二酸化ケイ素並びに二酸化ケイ素などが挙げられる。
本発明の医薬が、懸濁剤である場合、所望により添加剤として分散剤が用いられる。
分散剤としては、特に限定されないが、例えば、メチルセルロース、カルボキシメチルセルロースナトリウム及びヒドロキシプロピルメチルセルロースなどのセルロース類、ポリビニルアルコール、ポリビニルピロリドン及びカルボキシビニルポリマーなどの合成高分子化合物、ポリオキシエチレンアルキルエーテル、ポリオキシエチレンポリプロピレンアルキルエーテル、ソルビタン脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ポリオキシエチレングリセリン脂肪酸エステル、ポリエチレングリコール脂肪酸エステル、ショ糖脂肪酸エステル、ポリオキシエチレンヒマシ油、ポリオキシエチレン硬化ヒマシ油及びポリオキシエチレンポリオキシプロピレン重合体などの非イオン性界面活性剤、アルキルベタイン、アルキルアミドベタイン、アルキルスルホベタイン及びイミダゾリンなどの両性界面活性剤、並びに飽和高級脂肪酸塩、アルキルスルホン酸塩、アルキルエーテルスルホン酸塩及びポリオキシエチレンアルキルエーテルリン酸塩などの陰イオン性界面活性剤などが挙げられる。
陽イオン性界面活性剤としては、特に限定されないが、例えば、セチルトリメチルアンモニウムクロリド、ラウリルジメチルベンジルアンモニウムクロリド、テトラブチルアンモニウムクロリド及びジオクタデシルジメチルアンモニウムクロリドなどが挙げられる。
pH調節剤としては、特に限定されないが、例えば、ジイソプロパノールアミン、トリイソプロパノールアミン、トリエタノールアミン、水酸化カリウム、水酸化ナトリウム、クエン酸ナトリウム、リン酸、酒石酸、dl-リンゴ酸及び氷酢酸などが挙げられる。
キレート剤としては、特に限定されないが、例えば、エデト酸、シュウ酸、クエン酸、ピロリン酸、ヘキサメタリン酸、グルコン酸及びこれらの塩などが挙げられる。
保存剤としては、鼻内に許容され得る保存剤が好ましい。
保湿剤としては、特に限定されないが、例えば、グリセリン、プロピレングリコール及び1,3-ブチレングリコールなどが挙げられる。
架橋剤としては、特に限定されないが、例えば、アセトアルデヒド、ジメチルケトン及び硫酸アルミニウムなどが挙げられる。
清涼化剤としては、特に限定されないが、例えば、l-メントール、dl-カンフル、d-ボルネオール、ウイキョウ油、ハッカ油及びハッカ水などが挙げられる。
皮膜剤としては、特に限定されないが、例えば、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、メチルセルロース、ヒドロキシエチルメチルセルロース及びカルボキシメチルセルロースナトリウムなどの水に溶解性または膨潤性のセルロース材料、ポリビニルピロリドン(ポビドン)並びに架橋ポリビニルピロリドン(クロスポビドン)が挙げられる。
鼻腔内へは、1日当たり5×10-11~1gを1回~数回適用する。
喘息治療薬としては、例えば以下の薬剤が挙げられる。
吸入ステロイド薬又は鼻噴霧用ステロイド薬:ベクロメタゾンプロピオン酸エステル、フルチカゾンプロピオン酸エステル、ブデソニド、シクレソニド、モメタゾンフランカルボン酸エステル等;
吸入ステロイド薬と長時間作用型β2 刺激薬の合剤:サルメテロールキシナホ酸塩との配合剤、ホルモテロールフマル酸塩水和物との配合剤;
テオフィリン徐放製剤:テオドール、テオロング、スロービッド、ユニフィル、ユニコン、ネオフィリン、テオドリップ等;
短時間作用性テオフィリン薬:ネオフィリン、テオコリン、モノフィリン、アストモリジンD/M、アストフィリン、アルビナ坐剤等;
長時間作用性β2刺激薬: 吸入薬(LABA)/セレベント、貼付薬/ホクナリンテープ、経口薬/メプチン、スピロペント、ホクナリン、ベラチン、アトック、ブロンコリン等;
短時間作用性β2刺激薬(SABA): 吸入薬/アイロミール、サルタノール、メプチンエアー、ベロテックエロゾル等、経口薬/ベネトリン、アロテック、イノリン、レアノール、エフェドリン、イソパール・P等;
ロイコトリエン拮抗薬(受容体拮抗薬): オノン、アコレート、シングレア、キプレス等;
Th2 サイトカイン阻害薬: アイピーディ等;
ヒスタミンH1受容体拮抗薬: ゼスラン、ニポラジン、ザジテン、セルテクト、アレジオン等
メディエーター遊離抑制薬: インタール、リザベン、ソルファ、ロメット、ケタス、アレギサール、ペミラストン、タザノール、タザレスト等;
トロンボキサンA2 阻害薬: ベガ、ドメナン等;
トロンボキサンA2 拮抗薬: ブロニカ、バイナス等;
経口ステロイド薬: プレドニン、プレドニゾロン、メドロール、リンデロン、レダコート、デカドロン、コルソン、デキサメサゾン、パラメゾン等;
免疫抑制薬:シクロスポリン等;
インターロイキン4R(IL-4R)阻害剤:デュピリマブ等;
ヨウ素製剤:ヨウレチン等。
減圧乾燥したヘパリン類似物質(有機硫酸基25.8~37.3% w/w、D-グルクロン酸19.0~24.0% w/w、マルホ株式会社)を生理食塩水に溶解し、ヘパリン類似物質溶液(0.3、30及び3000 μg/mL)を作製した。好酸球性副鼻腔炎患者から摘出した鼻茸検体を約5 mm角に細切し、水分を拭き取り重量を測定した。各検体を12 wellプレートに移し、生理食塩水又は各濃度のヘパリン類似物質溶液を1 mL添加し、37°Cで約24時間インキュベートした。プレートから検体を取り出し、水分を拭き取り重量を測定した。インキュベーション前後の検体重量の差を、鼻茸縮小作用の指標として評価した。また、図1の生理食塩水群及び各濃度のヘパリン類似物質溶液群の例数は6例とした。
実施例1と同様の方法により、0.003、0.03、0.3及び30 μg/mL ヘパリン類似物質溶液の鼻茸縮小作用を評価した。また、図2の生理食塩水群及び各濃度のヘパリン類似物質溶液群の例数は6例とした。
実施例1と同様の方法により、PPS溶液(0.003μg/mL)を調製し、鼻茸縮小作用を評価した。PPSとして、Molclone Labs社製のペントサンポリ硫酸ナトリウム(重量平均分子量4000~6500、硫黄含量13.0~20.0%w/w、グルクロン酸含量2.5~4.0%w/w)を使用した。また、図3の生理食塩水群及びPPS溶液群の例数は6例とした。
実施例1と同様の方法により、下記の11種類の多糖の溶液(グルコマンナン以外はそれぞれ300μg/mL、グルコマンナンは30μg/mL)を調製し、鼻茸縮小作用を評価した。また、表1~4の生理食塩水群及び各多糖溶液群の例数は1例とした。
・コンドロイチン(コンドロイチンナトリウム、重量平均分子量42,351、硫酸基含量2.6%、マルホ株式会社製)
・低分子コンドロイチン硫酸(低分子コンドロイチン硫酸ナトリウム、重量平均分子量11,500、硫酸基含量硫酸基含量8.9%、マルホ株式会社製)
・コンドロイチン硫酸A(コンドロイチン硫酸Aナトリウム、株式会社PGリサーチ製)
・デルマタン硫酸(デルマタン硫酸ナトリウム、東京化成工業株式会社製)
・コンドロイチン硫酸C(コンドロイチン硫酸Cナトリウム、株式会社PGリサーチ製)
・グルコマンナン(プロポールA、清水化学株式会社製)
・デキストラン硫酸(デキストラン硫酸ナトリウム500,000、富士フイルム和光純薬株式会社製)
・ケラタン硫酸(ケラタン硫酸ナトリウム、株式会社PGリサーチ製)
・イヌリン(東京化成工業株式会社製)
・ヘパラン硫酸(Toronto Research Chemicals,Inc.製)
・キシロオリゴ糖(キシロヘキサオース、Megazyme製)
実施例1と同様の方法により、ヘパリン類似物質溶液及びPPS溶液(それぞれ0.03、0.3、30及び300μg/mL)を調製し、非好酸球性副鼻腔炎患者から摘出した鼻茸検体に対する鼻茸縮小作用を評価した。なお、ヘパリン類似物質及びPPSは、実施例1及び実施例3で使用したものと同じものを使用した。また、表5の生理食塩水群、ヘパリン類似物質溶液及びPPS溶液群の例数は1例とした。
Claims (8)
- 多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、デルマタン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、イヌリン、およびキシロオリゴ糖から選択される多糖又はその塩を有効成分とする鼻茸縮小剤。
- 前記多糖が、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、およびイヌリンから選択される、請求項1に記載の鼻茸縮小剤。
- 鼻腔内投与される、請求項1または2に記載の鼻茸縮小剤。
- 慢性副鼻腔炎患者の鼻茸の縮小に用いられる、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、デルマタン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、イヌリン、およびキシロオリゴ糖から選択される多糖又はその塩を含む医薬組成物。
- 前記多糖が、多硫酸化コンドロイチン硫酸、コンドロイチン硫酸、ケラタン硫酸、ヘパラン硫酸、デキストラン硫酸、ペントサンポリ硫酸、コンドロイチン、グルコマンナン、およびイヌリンから選択される請求項4に記載の医薬組成物。
- 前記慢性副鼻腔炎患者が、好酸球性副鼻腔炎又は非好酸球性副鼻腔炎患者である、請求項4または5に記載の医薬組成物。
- 前記慢性副鼻腔炎患者が、好酸球性副鼻腔炎患者である、請求項4~6のいずれか一項に記載の医薬組成物。
- 請求項4~7のいずれか一項に記載の医薬組成物を含む、鼻腔内投与製剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020349263A AU2020349263B2 (en) | 2019-09-20 | 2020-09-18 | Pharmaceutical composition |
BR112022003464A BR112022003464A2 (pt) | 2019-09-20 | 2020-09-18 | Composição farmacêutica |
JP2021546977A JP7313019B2 (ja) | 2019-09-20 | 2020-09-18 | 医薬組成物 |
CN202080064874.7A CN114650828A (zh) | 2019-09-20 | 2020-09-18 | 药物组合物 |
EP20864928.5A EP4032535A4 (en) | 2019-09-20 | 2020-09-18 | PHARMACEUTICAL COMPOSITION |
US17/760,901 US20220347093A1 (en) | 2019-09-20 | 2020-09-18 | Pharmaceutical composition |
CA3154360A CA3154360C (en) | 2019-09-20 | 2020-09-18 | Polysaccharides for nasal polyp reduction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019170955 | 2019-09-20 | ||
JP2019-170955 | 2019-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021054440A1 true WO2021054440A1 (ja) | 2021-03-25 |
Family
ID=74883058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/035438 WO2021054440A1 (ja) | 2019-09-20 | 2020-09-18 | 医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220347093A1 (ja) |
EP (1) | EP4032535A4 (ja) |
JP (1) | JP7313019B2 (ja) |
CN (1) | CN114650828A (ja) |
AU (1) | AU2020349263B2 (ja) |
BR (1) | BR112022003464A2 (ja) |
CA (1) | CA3154360C (ja) |
WO (1) | WO2021054440A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3144752A1 (fr) * | 2023-01-10 | 2024-07-12 | Song Huang | Utilisation de polysulfate de pentosane pour le traitement de la toux seche |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0762001A (ja) | 1993-08-24 | 1995-03-07 | Seikagaku Kogyo Co Ltd | 硫酸化糖の脱硫酸化方法 |
JPH09104636A (ja) | 1995-10-05 | 1997-04-22 | G O Medical Service:Kk | 鼻茸治療・予防剤 |
JPH10203988A (ja) | 1997-01-27 | 1998-08-04 | Meiji Milk Prod Co Ltd | 鼻茸および鼻粘膜の浮腫性病変の治療剤 |
JP2009503090A (ja) * | 2005-08-03 | 2009-01-29 | モリア・バイオファーマシューティカルズ | 嚢胞性線維症における脂質複合体の使用及びその適用 |
JP2013521300A (ja) * | 2010-03-03 | 2013-06-10 | ネオキュティス エスアー | 抗菌ペプチド隔離化合物を用いた皮膚疾患および皮膚障害の処置のための組成物および方法 |
JP2014534214A (ja) * | 2011-10-27 | 2014-12-18 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | 慢性副鼻腔炎の処置における脂質コンジュゲート |
JP6463351B2 (ja) | 2013-06-21 | 2019-01-30 | サノフィ・バイオテクノロジー | Il−4rアンタゴニストの投与により鼻茸を処置する方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11335288A (ja) * | 1998-05-20 | 1999-12-07 | Maruho Co Ltd | アレルギー性疾患の予防または治療薬 |
WO2000069917A1 (fr) * | 1999-05-18 | 2000-11-23 | Maruho Kabushikikaisha | Compositions medicinales destinees a inhiber le systeme kallikreine-kinine ou la phospholipase a¿2? |
US20140005115A1 (en) * | 2005-11-17 | 2014-01-02 | Yissum Research Development Company | Lipid conjugates in the treatment of bronchitis |
-
2020
- 2020-09-18 WO PCT/JP2020/035438 patent/WO2021054440A1/ja unknown
- 2020-09-18 BR BR112022003464A patent/BR112022003464A2/pt unknown
- 2020-09-18 US US17/760,901 patent/US20220347093A1/en active Pending
- 2020-09-18 AU AU2020349263A patent/AU2020349263B2/en active Active
- 2020-09-18 JP JP2021546977A patent/JP7313019B2/ja active Active
- 2020-09-18 CA CA3154360A patent/CA3154360C/en active Active
- 2020-09-18 CN CN202080064874.7A patent/CN114650828A/zh active Pending
- 2020-09-18 EP EP20864928.5A patent/EP4032535A4/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0762001A (ja) | 1993-08-24 | 1995-03-07 | Seikagaku Kogyo Co Ltd | 硫酸化糖の脱硫酸化方法 |
JPH09104636A (ja) | 1995-10-05 | 1997-04-22 | G O Medical Service:Kk | 鼻茸治療・予防剤 |
JPH10203988A (ja) | 1997-01-27 | 1998-08-04 | Meiji Milk Prod Co Ltd | 鼻茸および鼻粘膜の浮腫性病変の治療剤 |
JP2009503090A (ja) * | 2005-08-03 | 2009-01-29 | モリア・バイオファーマシューティカルズ | 嚢胞性線維症における脂質複合体の使用及びその適用 |
JP2013521300A (ja) * | 2010-03-03 | 2013-06-10 | ネオキュティス エスアー | 抗菌ペプチド隔離化合物を用いた皮膚疾患および皮膚障害の処置のための組成物および方法 |
JP2014534214A (ja) * | 2011-10-27 | 2014-12-18 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | 慢性副鼻腔炎の処置における脂質コンジュゲート |
JP6463351B2 (ja) | 2013-06-21 | 2019-01-30 | サノフィ・バイオテクノロジー | Il−4rアンタゴニストの投与により鼻茸を処置する方法 |
Non-Patent Citations (11)
Title |
---|
ALLERGOLOGY INTERNATIONAL, vol. 66, 2017, pages 594 - 602 |
BULLETIN OF THE JAPAN OTOLARYNGOLOGY SOCIETY, vol. 121, 2018, pages 1118 - 1120 |
FUJIEDA, SHIGEHARU : "From disease research to next-generation treatment, III. Allergic rhinitis, 2. Eosinophilic sinusitis", EXPERIMENTAL MEDICINE, vol. 37, no. 10, 15 June 2019 (2019-06-15), JP , pages 185 (1697) - 192 (1704), XP009535438, ISSN: 0288-5514 * |
INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, vol. 67, no. 3, September 2015 (2015-09-01), pages 299 - 307 |
KAWASAKI MEDICAL SCHOOL JOURNAL, vol. 35, no. 1, 2009, pages 39 - 50 |
OHNISHI NOBUKAZU: "Suppressive effect of fine grinding konjac glucomannan on scratching behavior and local cutaneous Th2 response in NC/Nga mice", JAPANESE JOURNAL OF ALLERGOLOGY, vol. 55, no. 8-9, 30 September 2006 (2006-09-30), pages 1124, XP055912797, ISSN: 0021-4884, DOI: 10.15036/arerugi.55.1124_2 * |
OTOLARYNGOLOGY IMMUNE ALLERGY, vol. 29, no. 3, 2011, pages 221 - 227 |
SANDEN CAROLINE, MORI MICHIKO, JOGDAND PRAJAKTA, JÖNSSON JIMMIE, KRISHNAN RAVI, WANG XIANGDONG, ERJEFÄLT JONAS S.: "Broad Th2 neutralization and anti-inflammatory action of pentosan polysu lfate sodium in experimental allergic rhinitis", IMMUN INFLAMM DIS., vol. 5, no. 3, 2017, pages 300 - 309, XP055807389 * |
See also references of EP4032535A4 |
SHINOBU SAKAI, HIROSHI AKIYAMA, YUJI SATO, YASUO YOSHIOKA, ROBERT J LINHARDT, YUKIHIRO GODA, TAMIO MAITANI, TOSHIHIKO TOIDA: "Chondroitin Sulfate Intake Inhibits the IgE-mediated Allergic Response by Down-regulating Th2 Responses in Mice", J BIOL CHEM., vol. 281, no. 29, 21 July 2006 (2006-07-21), pages 19872 - 19880, XP055807386 * |
TETSUJI TAKABAYASHI , ATSUSHI KATO, ANJU T PETERS, KATHRYN E HULSE, LYDIA A SUH, RODERICK CARTER, JAMES NORTON, LESLIE C GRAMMER, : "Excessive Fibrin Deposition in Nasal Polyps Caused by Fibrinolytic Impairment through Reduction of Tissue Plasminogen Activator Expression", AM J RESPIR GRIT CARE MED., vol. 187, no. 1, 2013, pages 49 - 57, XP055807393 * |
Also Published As
Publication number | Publication date |
---|---|
BR112022003464A2 (pt) | 2022-05-24 |
CA3154360C (en) | 2024-01-23 |
EP4032535A1 (en) | 2022-07-27 |
US20220347093A1 (en) | 2022-11-03 |
AU2020349263A1 (en) | 2022-04-14 |
CN114650828A (zh) | 2022-06-21 |
EP4032535A4 (en) | 2023-10-25 |
JP7313019B2 (ja) | 2023-07-24 |
AU2020349263B2 (en) | 2023-08-17 |
CA3154360A1 (en) | 2021-03-25 |
JPWO2021054440A1 (ja) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9814705B2 (en) | Intranasal spray device containing pharmaceutical composition | |
US20070054878A1 (en) | Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis | |
CA2838493C (en) | Applications of partially and fully sulfated hyaluronan | |
EP3370692B1 (en) | Stuffy nose deblocking composition having antiviral activity | |
US9937258B2 (en) | Composition for application to a nasal mucosa comprising a methylcellulose | |
US10179147B2 (en) | Applications of partially and fully sulfated hyaluronan | |
JP4961772B2 (ja) | 硫酸化セルロース及びその塩から選ばれた化合物並びに皮膚炎治療剤 | |
EP2844226B1 (en) | Ophthalmic compositions with improved dessication protection and retention | |
JP2005521629A (ja) | 関節炎の関節を治療するためのグリコサミノグリカンとヒアルロニダーゼ阻害剤を含んで成る組成物 | |
WO2006066500A1 (fr) | Procédé de synthèse de dérivés de quinazoline et application à la fabrication d'un médicament pour le traitement d'une maladie de type tumoral | |
WO2021054440A1 (ja) | 医薬組成物 | |
AU2003278962C1 (en) | Nasal compositions comprising a mucopolysaccharide and propylene glycol | |
CN118416094A (zh) | 药物组合物 | |
CN115209954B (zh) | 用于治疗呼吸***病变的组合物 | |
WO2024104313A1 (en) | Composition for antiviral or oxidation pretreatment, preparation method and usage method thereof | |
US20130203695A1 (en) | Hypersulfated disaccharides to treat elastase related disorders | |
US20070190081A1 (en) | Aqueous suspension for nasal drops | |
CN114404354A (zh) | 鼻用原位凝胶制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20864928 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022003464 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021546977 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3154360 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020349263 Country of ref document: AU Date of ref document: 20200918 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020864928 Country of ref document: EP Effective date: 20220420 |
|
ENP | Entry into the national phase |
Ref document number: 112022003464 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220223 |